Midjourney, the company best known for turning text prompts into AI-generated images, announced on June 18 that it is developing a full-body ultrasonic scanner intended to compete with MRI in speed, if not yet in clinical credibility. The device, called the Midjourney Scanner, is the first product from a newly named division, Midjourney Medical. The company plans to house the machines inside dedicated spas it will build and operate.
The hardware mechanism works like this: a person steps onto a platform and is slowly submerged in water at two inches per second, passing through a ring lined with roughly half a million ultrasound-emitting sensors, each the size of a grain of sand. Those sensors fire ultrasonic waves and record the reflections, building what Midjourney describes as a three-dimensional body map accurate to a fraction of a millimeter. The company claims this produces output that looks comparable to a full-body MRI, but in under 60 seconds instead of the 60 to 90 minutes a conventional MRI scan requires.
The technology is not being built from scratch. Midjourney signed a licensing agreement with Butterfly Network, a maker of handheld ultrasound-on-chip devices, in November 2025, securing exclusive rights to that chip technology. As Engadget reported, the project is led by Ahmad Abbas, who joined Midjourney in late 2023 after working on the Vision Pro at Apple.
The roadmap is ambitious and the milestones are tightly sequenced. Over the next 12 months, Midjourney says it will refine its algorithms, run research trials, and develop a second-generation hardware design. The first spa is planned for San Francisco sometime next year. FDA approval of the diagnostic capabilities is listed as a required step before broader deployment. A third-generation machine using custom silicon is targeted for 2028, and the company has set a goal of 50,000 scanners worldwide by 2031. Midjourney’s own announcement claims the technology could “avoid 30 percent of all deaths and 50 percent of all healthcare costs” with sufficient early adoption. No independent clinical data supports those figures.
The pivot is striking for a company with no prior hardware or medical product history. Ultrasonic imaging at the resolution Midjourney describes is a technically constrained problem: achieving MRI-comparable soft-tissue contrast through ultrasound has challenged dedicated medical device manufacturers for decades, and the physics of ultrasound make certain tissues (particularly those near bone or containing gas) difficult to resolve clearly. The company has not disclosed whether any clinical validation studies are underway, who would conduct them, or what the FDA submission timeline looks like. The distance between a compelling demo and a cleared diagnostic device can span years and hundreds of millions of dollars in regulated trial work.
The spa distribution model is also unusual for the medical imaging market, which typically routes imaging through clinical referral chains, insurance reimbursement systems, and licensed radiologists. Midjourney appears to be targeting a direct-to-consumer wellness positioning, at least initially, which sidesteps some regulatory burdens but also limits the device’s clinical utility until clearance is obtained.
The Butterfly Network licensing agreement gives Midjourney a credible ultrasound technology foundation. Whether the company can translate that foundation into a product that satisfies FDA diagnostic standards, at the cost and throughput implied by a spa model, is a question the next 18 months of regulatory engagement will begin to answer.
Companies building diagnostic hardware on abbreviated timelines before regulatory validation tend to run into one of two outcomes: a long, expensive compliance journey that reshapes the product, or a pivot back to wellness claims that avoids the regulatory burden but also limits the addressable market. Teams considering Midjourney’s scanner as a clinical tool should wait for peer-reviewed imaging data and FDA submission progress before assigning it meaningful probability in any roadmap.
Reporting by Mariella Moon, published by Engadget on June 18, 2026.
